LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Kodu・Aktsiate loetelu・Ardelyx Inc

Ardelyx Inc

Avatud

Sektor Tervishoid

5.73 -2.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.65

Max

5.88

Põhinäitajad
By Trading Economics
Sissetulek	-27M
Müük	12M 46M
Aktsiakasum	-0.11
Kasumimarginaal	-57.619
Töötajad	267
EBITDA	-22M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+78.57 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	-228M 1.4B
Eelmine avamishind	7.78
Eelmine sulgemishind	5.73

Uudiste sentiment

By Acuity

75%

25%

344 / 366 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

5.85 / 5.925 Toetus ja vastupanu

Ardelyx Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. okt 2024, 23:17 UTC

Peamised uudised

Australian Consumer Confidence Highest Since Early 2023

21. okt 2024, 20:42 UTC

Tulu

SAP 3Q Revenue, Profit Climb on AI Demand; Outlook Raised

21. okt 2024, 22:57 UTC

Tulu

Ping An Insurance: Higher Income From Healthcare, Senior-Care Services Supported Results >2318.HK

21. okt 2024, 22:57 UTC

Tulu

Ping An Insurance 9-Mos Rev CNY861.8B ; Up 8.7% on Year >2318.HK

21. okt 2024, 22:57 UTC

Tulu

Ping An Insurance 9-Mos Net CNY119.2B; Up 36.1% on Year >2318.HK

21. okt 2024, 22:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Webjet Looks Like an M&A Target, But Bids Unlikely Soon -- Market Talk

21. okt 2024, 21:02 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Deal Jitters Imperil Stock's Big Rebound -- Barrons.com

21. okt 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. okt 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. okt 2024, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

21. okt 2024, 20:32 UTC

Tulu

Nucor: The Earnings of the Raw Materials Segment Are Expected to Increase in 4Q Compared to 3Q >NUE

21. okt 2024, 20:31 UTC

Tulu

Nucor: Expect Consolidated Net Earnings Attributable to Nucor Stockholders in 4Q to Decrease >NUE

21. okt 2024, 20:30 UTC

Tulu

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

21. okt 2024, 20:30 UTC

Tulu

Nucor 3Q Steel Mills Total Shipments 5.72M Tons >NUE

21. okt 2024, 20:30 UTC

Tulu

Nucor 3Q Average Sales Price Per Ton Down 15% >NUE

21. okt 2024, 20:30 UTC

Tulu

Nucor 3Q EPS $1.05 >NUE

21. okt 2024, 20:30 UTC

Tulu

Nucor 3Q Sales $7.44B >NUE

21. okt 2024, 20:30 UTC

Tulu

Nucor 3Q Net $249.9M >NUE

21. okt 2024, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Glendon Capital Filing Mentions Reuters Article About Glendon Opposition to Verizon Deal

21. okt 2024, 20:20 UTC

Peamised uudised

Nvidia Reaches $3.5 Trillion Market Value. It's Right on Apple's Heels. -- Barrons.com

21. okt 2024, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Frontier Communications Shareholder Glendon Capital Will Continue to Engage in Talks With Relevant Parties About Sale to Verizon

21. okt 2024, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

21. okt 2024, 20:14 UTC

Peamised uudised

S&P 500, Dow Slip; Bond Yields Rise -- WSJ

21. okt 2024, 20:10 UTC

Tulu

SAP Backs 2024 Cloud Revenue EUR17B-EUR17.3B >SAP

21. okt 2024, 20:10 UTC

Tulu

SAP Raises 2024 Cloud and Software Revenue View to EUR29.5B-EUR29.8B >SAP

21. okt 2024, 20:08 UTC

Tulu

SAP Sees Exiting 2024 at Headcount Slightly Ahead of Year-End 2023 >SAP

21. okt 2024, 20:07 UTC

Tulu

SAP 3Q Cloud and Software Revenue EUR7.43B >SAP

21. okt 2024, 20:07 UTC

Tulu

SAP 3Q Software Licenses Revenue EUR280M>SAP

21. okt 2024, 20:06 UTC

Tulu

SAP 3Q Adj EPS EUR1.23 >SAP

21. okt 2024, 20:06 UTC

Tulu

SAP 3Q EPS EUR1.25 >SAP

Võrdlus sarnastega

Hinnamuutus

Ardelyx Inc Prognoos

Hinnasiht

By TipRanks

78.57% tõus

12 kuu keskmine prognoos

Keskmine 10.5 USD 78.57%

Kõrge 12 USD

Madal 7 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Ardelyx Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Ardelyx Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.85 / 5.925Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

344 / 366 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.